[Actual points of melanoma management].

The development of the therapy of advanced melanoma resulted in significant improvement of disease outcome; over 6 years of median survival was reached in the CheckMate 067 study. The new therapeutic modalities are already implemented in the clinical practice according to the current guidelines, however some diagnostic and therapeutic questions are still unresolved. We aimed to highlight the topic of therapeutic options for BRAF mutated melanomas, the role of PD-L1 ligand examination, the adequate therapy of oligoprogression, and the current indication of sentinel lymph node biopsy.